NASDAQ:OPHT - Ophthotech News Headlines Sign in or create an account to add this stock to your watchlist. Get Started $1.50 -0.05 (-3.23 %) (As of 03/21/2019 04:00 PM ET)Previous Close$1.55Today's Range$1.49 - $1.5552-Week Range$1.02 - $4.50Volume144,324 shsAverage Volume294,776 shsMarket Capitalization$62.13 millionP/E Ratio-0.90Dividend YieldN/ABeta1.49 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Headlines Ophthotech (NASDAQ OPHT) News Headlines Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance DateHeadlineOphthotech Corpwww.bloomberg.com - March 19 at 8:30 AMOphthotech to Present at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell & Gene Therapy Investor Dayfinance.yahoo.com - March 14 at 8:21 AMIf You Had Bought Ophthotech (NASDAQ:OPHT) Stock Three Years Ago, You’d Be Sitting On A 96% Loss, Todayfinance.yahoo.com - March 12 at 10:53 PM Brokerages Expect Ophthotech Corp (OPHT) Will Post Earnings of -$0.36 Per Sharewww.americanbankingnews.com - March 10 at 10:25 AMOphthotech to Present at the Cowen and Company 39th Annual Health Care Conferencefinance.yahoo.com - March 6 at 8:21 AMOphthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focuswww.zacks.com - February 27 at 7:25 PMEdited Transcript of OPHT earnings conference call or presentation 26-Feb-19 1:00pm GMTfinance.yahoo.com - February 27 at 8:14 AMBRIEF-Ophthotech Reports Q4 And FY2018 Financial Resultswww.msn.com - February 26 at 6:47 PMOphthotech Corporation (OPHT) CEO Glenn Sblendorio on Q4 2018 Results - Earnings Call Transcriptseekingalpha.com - February 26 at 6:47 PMOphthotech Corp (OPHT) Reports Q4 EPS of $2.62 - StreetInsider.comwww.streetinsider.com - February 26 at 8:15 AMOphthotech Reports Fourth Quarter and Full Year 2018 Financial and Operating Resultsfinance.yahoo.com - February 26 at 8:15 AMU.S. STOCKS ON THE MOVE- GE, Spark Therapeutics, IMAX - Nasdaqwww.nasdaq.com - February 25 at 7:08 PMU.S. STOCKS ON THE MOVE-GE, Spark Therapeutics, chip stocks - Nasdaqwww.nasdaq.com - February 25 at 7:08 PMU.S. STOCKS ON THE MOVE-GE, Anaplan, Nio, Titan Pharmaceuticals, Spark Therapeutics - Nasdaqwww.nasdaq.com - February 25 at 7:08 PMOphthotech Corporation to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, February 26, 2019finance.yahoo.com - February 19 at 8:11 AMRecent Analysis Shows Amerco, McKesson, Ophthotech, IQVIA, Highwoods Properties, and ABM Industries Market Influences — Renewed Outlook, Key Drivers of Growthfinance.yahoo.com - February 8 at 8:13 AMOphthotech (OPHT) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshowseekingalpha.com - January 11 at 6:45 PMOphthotech Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 8:16 AMOphthotech Announces the Addition of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., to Its Board of Directorsfinance.yahoo.com - January 2 at 8:16 AMOphthotech Announces the Addition of Ophthalmic Industry Leader, Adrienne L. Graves, Ph.D., Former Chief Executive Officer of Santen Inc., to Its Board of Directorsfinance.yahoo.com - December 12 at 4:22 PMOphthotech (OPHT) Down 21.7% Since Last Earnings Report: Can It Rebound?finance.yahoo.com - November 30 at 5:58 PMOphthotech Corp (OPHT) Reports Results from Phase 2a Safety Trial of Zimura (avacincaptad pegol) in Combination ...www.streetinsider.com - November 14 at 5:24 PMBRIEF-Ophthotech Announces Results From Phase 2A Safety Trial Of Zimura In Combination With Lucentis In Wet Age-Related Macular Degenerationwww.msn.com - November 12 at 8:17 AMOphthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degenerationfinance.yahoo.com - November 12 at 8:17 AMForm 10-Q Ophthotech Corp. For: Sep 30www.streetinsider.com - November 4 at 8:16 AMForm 8-K Ophthotech Corp. For: Oct 30www.streetinsider.com - November 2 at 8:09 AMOphthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focusfinance.yahoo.com - November 1 at 6:11 PMEdited Transcript of OPHT earnings conference call or presentation 31-Oct-18 12:00pm GMTfinance.yahoo.com - November 1 at 8:07 AMOphthotech Corporation 2018 Q3 - Results - Earnings Call Slidesseekingalpha.com - October 31 at 5:35 PMOphthotech Corporation (OPHT) CEO Glenn Sblendorio on Q3 2018 Results - Earnings Call Transcriptseekingalpha.com - October 31 at 5:35 PMOphthotech acquires Inception 4 in all-stock dealseekingalpha.com - October 31 at 8:13 AMOphthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4finance.yahoo.com - October 31 at 8:13 AMOphthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)finance.yahoo.com - October 31 at 8:13 AMOphthotech Reports Third Quarter 2018 Financial and Operating Resultsfinance.yahoo.com - October 31 at 8:13 AMOphthotech: 3Q Earnings Snapshotfinance.yahoo.com - October 31 at 8:13 AMOphthotech Corporation to Report Third Quarter 2018 Financial Results and Host Conference Call on Wednesday ...www.businesswire.com - October 23 at 8:11 AMOphthotech Corporation to Report Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, October 31, 2018finance.yahoo.com - October 23 at 8:11 AMForm 8-K Ophthotech Corp. For: Oct 04www.streetinsider.com - October 5 at 8:16 AMOphthotech completes patient recruitment for its Phase 2b clinical trial of Zimuraseekingalpha.com - October 4 at 4:56 PMOphthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura® Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degenerationfinance.yahoo.com - October 4 at 8:11 AMOphthotech Corporation to Present at Chardan’s 2nd Annual Genetic Medicines Conferencefinance.yahoo.com - October 3 at 8:17 AMIs Ophthotech Corporation (NASDAQ:OPHT) Attractive At Its Current PE Ratio?finance.yahoo.com - September 12 at 4:54 PMWhy Is Ophthotech (OPHT) Up 5.8% Since Last Earnings Report?finance.yahoo.com - August 31 at 5:19 PMOphthotech Corp (OPHT) Says Data for Adeno-Associated Virus Gene Therapy in RHO-adRP Published in PNASwww.streetinsider.com - August 22 at 5:04 PMScientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciencesfinance.yahoo.com - August 22 at 8:17 AMReport: Developing Opportunities within Energy Recovery, Lamb Weston, Neurocrine Biosciences, Pioneer Natural Resources, Meritor, and Ophthotech — Future Expectations, Projections Moving into 2018finance.yahoo.com - August 13 at 8:09 AMForm 10-Q Ophthotech Corp. For: Jun 30www.streetinsider.com - August 3 at 4:40 PMEdited Transcript of OPHT earnings conference call or presentation 1-Aug-18 12:00pm GMTfinance.yahoo.com - August 2 at 8:12 AMOphthotech Corp (OPHT) CEO Glenn Sblendorio on Q2 2018 Results - Earnings Call Transcriptseekingalpha.com - August 1 at 5:59 PMOphthotech Corp (OPHT) Tops Q2 EPS by 2cwww.streetinsider.com - August 1 at 5:59 PM This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: How accurate is the Rule of 72?